Methotrexate is under clinical development by Hubei Soundny Bio-Tech and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Methotrexate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Methotrexate is under development for the treatment of recrruent and refractory ovarian cancer, malignant pleural effusion and non-small cell lung cancer. The drug candidate is administered as an intrapleural and peritoneal infusion. The drug candidate is based on vesicles technology platform. Methotrexate acts by targeting dihydrofolate reductase (DHF).
Hubei Soundny Bio-Tech overview
Hubei Soundny Bio-Tech is a biotechnology company. Specializing in the research, development, application and promotion of drug-loaded vesicle treatment for cancer technology. It is headquartered in Wuhan, Hubei, China.
For a complete picture of Methotrexate’s drug-specific PTSR and LoA scores, buy the report here.